Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

被引：2
|
作者：
Kurzrock, Razelle [1 ]
Voorhees, Peter M. [2 ]
Casper, Corey [3 ]
Furman, Richard R. [4 ]
Fayad, Luis [1 ]
Lonial, Sagar [5 ]
Borghaei, Hossein [6 ]
Jagannath, Sundar [7 ]
Sokol, Lubomir [8 ]
Usmani, Saad [9 ]
van de Velde, Helgi [10 ]
Qin, Xiang [11 ]
Qi, Ming [11 ]
Cornfeld, Mark J. [12 ]
van Rhee, Frits [13 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] St Vincents Comprehens Canc Ctr, New York, NY USA
[8] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[9] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[10] Janssen Res & Dev, Beerse, Belgium
[11] Ortho Biotech Oncol Res & Dev, Malvern, PA USA
[12] Ortho Biotech Oncol Res & Dev, Raritan, NJ USA
[13] Bon Secours St Francis Hlth Syst, Hematol Oncol, Greenville, SC USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3959.3959
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：1693 / 1693
页数：1
相关论文
共 50 条
  • [41] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2010, 116 (21) : 1148 - 1149
  • [42] Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
    Benjamin, J. E.
    Chen, G. L.
    Cao, T. M.
    Cao, P. D.
    Wong, R. M.
    Sheehan, K.
    Shizuru, J. A.
    Johnston, L. J.
    Negrin, R. S.
    Lowsky, R.
    Laport, G. G.
    BONE MARROW TRANSPLANTATION, 2010, 45 (02) : 303 - 309
  • [43] Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
    J E Benjamin
    G L Chen
    T M Cao
    P D Cao
    R M Wong
    K Sheehan
    J A Shizuru
    L J Johnston
    R S Negrin
    R Lowsky
    G G Laport
    Bone Marrow Transplantation, 2010, 45 : 303 - 309
  • [44] Blood Erythrocyte Concentrations of Cadmium and Lead and the Risk of B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: A Nested Case-Control Study
    Kelly, Rachel S.
    Lundh, Thomas
    Porta, Miquel
    Bergdahl, Ingvar A.
    Palli, Domenico
    Johansson, Ann-Sofie
    Botsivali, Maria
    Vineis, Paolo
    Vermeulen, Roel
    Kyrtopoulos, Soterios A.
    Chadeau-Hyam, Marc
    PLOS ONE, 2013, 8 (11):
  • [45] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    Robinson, K. Sue
    Williams, Michael E.
    van der Jagt, Richard H.
    Cohen, Philip
    Herst, Jordan A.
    Tulpule, Anil
    Schwartzberg, Lee S.
    Lemieux, Bernard
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4473 - 4479
  • [46] Long-term survival after histologic transformation from high grade B cell non-Hodgkin's lymphoma to low grade follicular lymphoma and Hodgkin's disease in the same patient
    Tolosa, A.
    Escriva, A.
    Ros, J.
    Garcia, A.
    Fernandez, M.
    Sayas, M. J.
    Andreu, R.
    Ribas, P.
    Cejalvo, M. J.
    Ferrer, S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S23 - S23
  • [47] Randomized controlled study of I-131-Anti-B1 versus unlabeled-Anti-B1 monoclonal antibody in patients with chemotherapy refractory low grade non-Hodgkin's lymphoma
    Knox, SJ
    Goris, ML
    Davis, TA
    Trisler, KD
    Saal, J
    Levy, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 326 - 326
  • [48] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [49] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [50] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
12345